ResMed (NYSE: RMD) reported Q4 EPS of $2.95, $0.06 better than the analyst estimate of $2.89. Revenue for the quarter came in at $1.46 billion versus the consensus estimate of $1.47 billion.

For earnings history and earnings-related data on ResMed (RMD) click here.